169 related articles for article (PubMed ID: 38583073)
41. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause.
Sarri G; Pedder H; Dias S; Guo Y; Lumsden MA
BJOG; 2017 Sep; 124(10):1514-1523. PubMed ID: 28276200
[TBL] [Abstract][Full Text] [Related]
42. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
43. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
[TBL] [Abstract][Full Text] [Related]
44. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis.
Toulis KA; Tzellos T; Kouvelas D; Goulis DG
Clin Ther; 2009 Feb; 31(2):221-35. PubMed ID: 19302896
[TBL] [Abstract][Full Text] [Related]
45. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis.
Liu T; Chen S; Mielke GI; McCarthy AL; Bailey TG
Climacteric; 2022 Dec; 25(6):552-561. PubMed ID: 35904028
[TBL] [Abstract][Full Text] [Related]
46. Exercise for vasomotor menopausal symptoms.
Daley A; Stokes-Lampard H; Thomas A; MacArthur C
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD006108. PubMed ID: 25431132
[TBL] [Abstract][Full Text] [Related]
47. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
48. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
Franco OH; Chowdhury R; Troup J; Voortman T; Kunutsor S; Kavousi M; Oliver-Williams C; Muka T
JAMA; 2016 Jun; 315(23):2554-63. PubMed ID: 27327802
[TBL] [Abstract][Full Text] [Related]
49. Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
Onge ES; Phillips B; Miller L
J Pharm Technol; 2023 Dec; 39(6):291-297. PubMed ID: 37974591
[No Abstract] [Full Text] [Related]
50. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.
Maclennan AH; Broadbent JL; Lester S; Moore V
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD002978. PubMed ID: 15495039
[TBL] [Abstract][Full Text] [Related]
51. Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; Wilkinson J; Basevi V; Marata AM; Magrini N; D'Amico R; Bassi C; Maestri E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD008536. PubMed ID: 27733017
[TBL] [Abstract][Full Text] [Related]
52. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
[TBL] [Abstract][Full Text] [Related]
53. A review of paroxetine for the treatment of vasomotor symptoms.
Slaton RM; Champion MN; Palmore KB
J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
[TBL] [Abstract][Full Text] [Related]
54. Management of Menopause Symptoms with Acupuncture: An Umbrella Systematic Review and Meta-Analysis.
Befus D; Coeytaux RR; Goldstein KM; McDuffie JR; Shepherd-Banigan M; Goode AP; Kosinski A; Van Noord MG; Adam SS; Masilamani V; Nagi A; Williams JW
J Altern Complement Med; 2018 Apr; 24(4):314-323. PubMed ID: 29298078
[TBL] [Abstract][Full Text] [Related]
55. Early-onset vasomotor symptoms and development of depressive symptoms among premenopausal women.
Choi HR; Chang Y; Park J; Cho Y; Kim C; Kwon MJ; Kang J; Kwon R; Lim GY; Ahn J; Kim KH; Kim H; Hong YS; Park J; Zhao D; Cho J; Guallar E; Park HY; Ryu S
J Affect Disord; 2024 Jun; 354():376-384. PubMed ID: 38503358
[TBL] [Abstract][Full Text] [Related]
56. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
Crespo C; Erlich D
Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
[No Abstract] [Full Text] [Related]
57. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.
Carris N; Kutner S; Reilly-Rogers S
Ann Pharmacother; 2014 Oct; 48(10):1343-9. PubMed ID: 25028744
[TBL] [Abstract][Full Text] [Related]
58. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
[No Abstract] [Full Text] [Related]
59. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
Utian WH
Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
[TBL] [Abstract][Full Text] [Related]
60. Neurokinin 3 receptor antagonism for menopausal hot flashes.
Comninos AN; Dhillo WS
Cell; 2023 Aug; 186(16):3332-3332.e1. PubMed ID: 37541194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
